This is a developing story. Please check back for updates. | After a tumultuous tenure marked by recent clashes with the ...

Flagship Pioneering-backed Alltrna is once again laying off staff, this time reducing its workforce by 19 people. | Flagship ...

In a strikingly blunt briefing, a senior FDA official accused uniQure of pushing “distorted” data to mask a “failed” therapy ...

After its latest pipeline clear-out, Merck KGaA is no longer pursuing any clinical-stage cancer candidates obtained through ...

Zealand Pharma’s Roche-partnered amylin analog demonstrated “placebo-like tolerability” and up to 10.7% mean weight loss at ...

Venture capital firm Portal Innovations is planning to open a 30,000-square-foot science incubator in Salt Lake City while ...

The FDA will end a roughly nine-month hiatus of drug-related advisory committee meetings, with plans to convene its first session of 2026 to scrutinize a pair of oncology applications from AstraZen | ...

With colon cancer deaths rising among younger adults and millions of eligible Americans skipping their colonoscopies, Guardant Health is taking its Shield blood test on the road in hopes of tackling ...

Two weeks after Teva touted promising long-term data for its Sanofi-partnered bowel disease drug, the Israeli pharma ...

Roche is plugging 710 billion won (about $484 million) into South Korea’s biopharma industry, with the goal of attracting ...

United Therapeutics has linked a once-daily drug candidate to a 55% drop in the risk of clinical worsening in a phase 3 trial ...

ARPA-H’s new lymphatic effort was announced on the same day as a $75.8 million program called OCULAB, which seeks to develop ...